CDC6 is a possible biomarker for hepatocellular carcinoma

xlomafota13 shared this article with you from Inoreader CDC6 is a possible biomarker for hepatocellular carcinoma Via International Journal of Clinical and Experimental Pathology Int J Clin Exp Pathol. 2021 Jul 15;14(7):811-818. eCollection 2021. ABSTRACT OBJECTIVE: Research has proven that the expression of CDC6 is tightly related to tumorigenesis and progression of various tumors. However, the effects of CDC6 in hepatocellular carcinoma remain uncertain. The main purpose of this research is to explore this relationship. METHODS: We assessed the expression levels of CDC6 in a serious of cancers from GEPIA database. The expression of CDC6 in hepatocellular carcinoma tissue and normal liver tissue was compared, and further assessed by immunohistochemical staining. Graphpad software was performed for data analysis, and t-test and χ2 analysis were used to investigate the role of CDC6 in hepatocellular carcinoma. RESULTS: The expression level of CDC6 was significantly higher in malignant carcinoid, melanoma, urothelial tumor, and hepatocellular carcinoma in the GEPIA online database. It was related to clinical progression of hepatocellular carcinoma. We found that the expression of CDC6 was correlated with tumor size (P=0.018) and the number of tumor nodes (P=0.003), but not with age, gender and AFP value (P>0.05). CONCLUSIONS: The expression level of CDC6 in hepatocellular carcinoma is related tightly to clinical findings. Detecting the expression of CDC6 might provide a new biomarker for patients with hepatocellular carcinoma. PMID:34367412 | PMC:PMC8 339721 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.